![]() It is unknown if HF with preserved ejection fraction (HFpEF)Īlso increases the risk. Introduction: Heart failure (HF) with reduced ejection fraction (HFrEF) is a risk factor for drug-induced Stratify the risk of lethal events in patients with BrS without history of VF or CPA. Independent predictor for VF/CPA (HR=1.69, 95%CI=1.04-2.79, p=0.03).Conclusion: Longer OT-CT in the MCG may noninvasively demonstrate substrate of VF in BrS and Among asymptomatic BrS patients (n=131), OT-CT≥65ms was also an (HR=1.72, 95%CI=1.16-2.62) were the independent predictor for lethal events in theīrS without VF/CPA. Multivariate Cox proportionalĪnalysis revealed that previous syncope (HR=1.70, 95%CI:1.01-3.05, p=0.04) and OT-CT≥65ms Whereas, spontaneous type-1 ECG, late potential of SAECG, family history, and VF inducibilityīy PES were not associated with VF/CPA events during follow-up. Operating curve (ROC) revealed OT-CT=65ms was a cut-off value of VF/CPA (AUC=0.78), 55☒4ms, p=0.01) compared with event-free patients. During follow-up (mean 72 months), 10 (6%) patients suffered VF/CPA,Īnd those had a higher incidence of previous syncope (50% vs. Reversed the pilsicainide-induced delayed OT-CT, thus normalized the ST elevation OT-CT (54☑8 to 127☖2 ms p<0.05), whereas additional isoproterenol (1ug/kg/min) Na channel blocker, pilsicainide (25-50mg) unmasked type-1 ECG as well as increased Programmed electrical stimulation (PES) for VF induction was performed in 47 patients.Results: Patients with spontaneous type-1 ECG had longer OT-CT compared with type-2 BrS patients. In all patients as well as the standard 12-lead ECG and signal-averaged ECG (SAECG). Outflow tract conduction time (OT-CT) from 2-D current map of MCG was measured VF/SCD.Methods: This study retrospectively enrolled 157 BrS patients without VF or cardiopulmonaryĪrrest (CPA) (150 male, 42☑3 years old, 118 spontaneous and 39 drug-induced type-1ĮCG). Magnetocardiography (MCG) could predict lethal events of the BrS without history of Here we investigated whether a high spatial resolution Implantable cardioverter defibrillator (ICD) for primary prevention of SCD is still Ventricular fibrillation (VF)/sudden cardiac death (SCD), thus to whom we should recommend Introduction: Many of the Brugada syndrome (BrS) patients have no symptom or only syncope without ![]() Of a clinical risk score used to discern non-cardiac death and true device malfunction The variables identified in this study will aid in the development (p< 0.01).Conclusions: There is variability and inaccuracy among expert physicians' interpretation of EGMsĭuring non-cardiac death. Post-survey scores ranged from 75 – 100% with a mean of 86.3% Pre-survey scores ranged from 50 – 87.5% correct Survey response rate was 68.8% and 62.5% for the SPs and PPVs of 100% for non-cardiac death but were less sensitive (60% and 20%, respectively).Īn abrupt change following therapy and response to therapy both had SNs, SPs, and Cycle length <130 ms and absence of discernible deflections both had Specificity (SP) of 100%, and positive predictive value (PPV) of 100% for non-cardiac Were shared, and the survey was readministered.Results: In our sample, absence of organized atrial activity had a sensitivity (SN) of 78.5%, Non-cardiac death and true arrhythmias in our sample was evaluated. The statistical performance of each variable for detecting Several variables were identified as important for theĬorrect classification of EGMs. UsingĪ subset of identified EGMs, an 8-question survey was administered to electrophysiologistsīlinded to cause of death. Were identified and compared to a control cohort of true arrhythmic events. Deaths were adjudicatedĪs non-cardiac based on direct clinical data at the time of death using a modifiedĬardiac Arrhythmia Suppression Trial approach. Terminal EGM features that may aid clinicians in discerning cardiac from non-cardiacĭeath.Methods: Terminal EGMs were analyzed by independent physician reviewers. While few studies have described the nature of terminal EGMs in non-cardiacĭeath, it is clinically and medicolegally important to characterize these EGMs toĮlucidate events that may otherwise be misinterpreted as device failure. Introduction: Electrograms (EGMs) generated by implantable cardiac devices at the time of non-cardiacĭeath may have artifact from non-arrhythmic sources, such as coagulated blood andĪir bubbles. Customer Service and Ordering Information.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes. ![]() Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |